https://
top of page

The Latest Milestones & News

Cord Blood & Tissue Stem Cells​

StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy

August 29, 2022

​

BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte is pleased to announce it has received approval from the U.S. Food and Drug Administration (FDA) for their Phase II clinical trial for Post-COVID Syndrome (or PCS) using umbilical cord blood stem cell therapy. PCS is also referred to as Long COVID and is characterized by lingering health effects or symptoms that are not explained by tests, which could last years.

 

Read More!

​

bottom of page